Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 229.78M P/E - EPS this Y 68.00% Ern Qtrly Grth -
Income -107.83M Forward P/E -1.54 EPS next Y 11.70% 50D Avg Chg -48.00%
Sales 2.4M PEG 0.00 EPS past 5Y - 200D Avg Chg -61.00%
Dividend N/A Price/Book 4.33 EPS next 5Y 294.10% 52W High Chg -77.00%
Recommedations 2.20 Quick Ratio 2.09 Shares Outstanding 40.74M 52W Low Chg 34.00%
Insider Own 20.06% ROA -63.62% Shares Float 29.73M Beta 0.28
Inst Own 21.83% ROE - Shares Shorted/Prior 697.63K/731.19K Price 7.88
Gross Margin 43.11% Profit Margin - Avg. Volume 2,705,837 Target Price 6.83
Oper. Margin -1,489.13% Earnings Date Nov 12 Volume 1,419,617 Change 5.07%
About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BioXcel Therapeutics, Inc. News
04:47 PM BioXcel Therapeutics Announces Proposed Public Offering
11/15/24 BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ...
11/14/24 Q3 2024 BioXcel Therapeutics Inc Earnings Call
11/14/24 BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates
11/14/24 BioXcel Therapeutics Reports Third Quarter 2024 Financial Results
11/12/24 BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia
11/08/24 BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
11/05/24 Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know
10/29/24 BioXcel Therapeutics to Present at ThinkEquity Conference
10/15/24 BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder
09/19/24 BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation
09/05/24 BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
08/30/24 BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
08/07/24 BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
08/07/24 Q2 2024 BioXcel Therapeutics Inc Earnings Call
08/06/24 BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates
08/06/24 BioXcel Therapeutics Reports Second Quarter 2024 Financial Results
07/30/24 BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024
07/16/24 BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film
06/25/24 BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia
BTAI Chatroom

User Image Moneymode2021 Posted - 32 minutes from now

$BTAI thoughts?

User Image Ksmith614 Posted - 2 hours ago

$BTAI such a BAD!!! place to have put my money in! stock market on fire now for 12 months This just continues to move down and its in a slow death spiral. I far in I cant add or move the little I have left. Fire the whole BOD and the CEO please sell the company for 10 to 17 if at all possible. I need it to reach 25 to beak even. I never thought this would go this low??

User Image BEARHODL Posted - 2 days ago

$BTAI it's gonna print next week

User Image slickinvest Posted - 2 days ago

$BTAI

User Image zrosiez Posted - 2 days ago

$BTAI I think they’ll get it back over 1, but I avoid all small biotech stocks.

User Image Ernesto062 Posted - 3 days ago

$BTAI finally Drops

User Image Stocksrockman Posted - 3 days ago

$BTAI $MRAI $ZONE Agree with your choices and wisdom

User Image SqueezeMagnet Posted - 3 days ago

$MRAI $BTAI were green on Friday Good job fighting the tuff market. $ZONE My #1 watch for Monday . It's so ready . Be early . 😇🧤

User Image khong_minh Posted - 4 days ago

$BTAI strong buy

User Image SqueezeMagnet Posted - 4 days ago

$ZONE It will run free !!! It's ready ! Squeeze imminent . 😇 $BENF Bottom again $BTAI Bottom bounced 👀 $STAX on watch

User Image slickinvest Posted - 6 days ago

$BTAI

User Image BEARHODL Posted - 6 days ago

$BTAI lowest price you will get IMO buy red 🫴🎁✍️✨️💎🚀🍻

User Image Maineusa1 Posted - 6 days ago

$BTAI has been done that is 😂

User Image Maineusa1 Posted - 6 days ago

$BTAI How many reiterations has been of a done over the years ? The stock is 50 cents for gods sake.

User Image PolyesterJacket Posted - 6 days ago

$BTAI Any day now @SkumFuxx

User Image Ernesto062 Posted - 6 days ago

$BTAI Bank of America Securities Reaffirms Their Buy Rating on Bioxcel Therapeutics (BTAI) Target Price 6 funny

User Image slickinvest Posted - 6 days ago

$BTAI

User Image fosback11 Posted - 6 days ago

$BTAI $40M cash with $25M in outstanding bills to pay. And $104M in debt at 14% interest. Do the math.

User Image Evissamwohs Posted - 6 days ago

$BTAI I do have to admit this company has blown the word disappointment out of the water! I did have confidence they would pull out of this eventually but that doesn’t look possible now.

User Image EchtLiebe Posted - 6 days ago

$BTAI

User Image BrahmaBear Posted - 1 week ago

$BTAI so what now? Just hold til it goes to zero? Sell at ATL?

User Image Ernesto062 Posted - 1 week ago

$BTAI wtf?

User Image LexiSexy Posted - 1 week ago

$BTAI garbage 🗑

User Image Ksmith614 Posted - 1 week ago

$BTAI the beginning of the end! go down quick and fire everyone and close down

User Image Moneymode2021 Posted - 1 week ago

$BTAI dead rat.

User Image Ernesto062 Posted - 1 week ago

$BTAI Game over

User Image Montyx Posted - 1 week ago

$BTAI thank god I sold at 3 bucks.

User Image fosback11 Posted - 1 week ago

$BTAI There it is finally in the 10Q -the first warning that major dilution to existing shareholders may occur. We expect that we will need to obtain substantial additional funding to fund our ongoing operations and planned trials. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, the ownership interests of our existing stockholders may be materially diluted, and the terms of these securities could include liquidation or other preferences that could adversely affect the rights of our existing stockholders.

User Image fosback11 Posted - 1 week ago

$BTAI Key statement in 10Q Management believes that, after giving effect to the Reprioritization and additional restructuring activities completed, the Company’s cash and cash equivalents of $40,837 as of September 30, 2024 will allow the Company to fund its operations and meet its liquidity requirements through the end of 2024.

User Image fosback11 Posted - 1 week ago

$BTAI Per 10Q, the interest they are paying for the $104M in debt is 14%.

Analyst Ratings
HC Wainwright & Co. Buy Sep 6, 24
Canaccord Genuity Buy Aug 30, 24
UBS Neutral Aug 9, 24
HC Wainwright & Co. Buy Aug 8, 24
Canaccord Genuity Buy Jun 27, 24
HC Wainwright & Co. Buy May 10, 24
HC Wainwright & Co. Buy Apr 23, 24
HC Wainwright & Co. Buy Mar 18, 24
Canaccord Genuity Buy Mar 14, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Mehta Vimal CEO and President CEO and President Jun 14 Sell 21.22 60,000 1,273,200 39,903 06/16/23
Mehta Vimal CEO and President CEO and President Jun 14 Option 0.41 60,000 24,600 69,903 06/16/23
Steinhart Richard I Chief Financial Offi.. Chief Financial Officer May 14 Sell 27.17 5,000 135,850 1,500 05/16/23
Rodriguez Javier See Remarks See Remarks May 14 Sell 27.32 1,785 48,766 4,350 05/16/23
Nandabalan Krishnan Director Director Apr 06 Sell 17.32 60,000 1,039,200 04/10/23
Nandabalan Krishnan Director Director Apr 06 Option 0.41 60,000 24,600 60,000 04/10/23
Mehta Vimal CEO and President CEO and President Mar 20 Sell 19 64,500 1,225,500 15,894 03/22/23
Mehta Vimal CEO and President CEO and President Mar 20 Option 0.41 60,000 24,600 45,894 03/22/23
Yocca Frank Chief Scientific Off.. Chief Scientific Officer Jan 20 Sell 30.00 50,000 1,500,000 8,397 01/24/23
O'Neill Vincent Chief Medical Office.. Chief Medical Officer Jan 20 Sell 30 29,713 891,390 01/24/23
O'Neill Vincent Chief Medical Office.. Chief Medical Officer Jan 20 Option 0.41 29,713 12,182 29,713 01/24/23
Nandabalan Krishnan Director Director Jan 04 Sell 22.26 60,000 1,335,600 01/06/23
Nandabalan Krishnan Director Director Jan 04 Option 0.41 60,000 24,600 25,889 01/06/23
Mehta Vimal CEO and President CEO and President Dec 15 Option 0.41 60,000 24,600 39,957 12/19/22
Mehta Vimal CEO and President CEO and President Dec 15 Sell 19.8 60,000 1,188,000 9,957 12/19/22
O'Neill Vincent Chief Medical Office.. Chief Medical Officer Feb 19 Option 5.71 25,000 142,750 25,000 02/19/21
O'Neill Vincent Chief Medical Office.. Chief Medical Officer Feb 19 Sell 55.51 25,000 1,387,750 02/19/21
Yocca Frank Chief Scientific Off.. Chief Scientific Officer Jan 27 Option 0.41 15,000 6,150 103,397 01/27/21